Skip to main content
SpringerLink
Log in

Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy

  • Book
  • © 1991

Overview

Editors:
  1. Stephen B. Howell

    1. University of California, San Diego, La Jolla, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (51 chapters)

  1. Clinical Trials

    1. High-Dose Carboplatin with Peripheral Blood Stem Cell and Growth Factor Support

      • Thomas C. Shea, James R. Mason, Anna Maria Storniolo, Barbara Newton, Margaret Breslin, Michael Mullen et al.
      Pages 433-439

    2. Pharmacologic, Pre-clinical and Clinical Investigations of the Cisplatin/Taxol Combination

      • Eric K. Rowinsky, William P. McGuire, Dennis A. Noe, Mark R. Gilbert, Martin J. Citardi, Ross C. Donehower
      Pages 441-452

    3. Phase I Trials with Ormaplatin (Tetraplatin)

      • Michaele C. Christian, David Spriggs, Kendra D. Tutsch, Timothy O’Rourke, Daniel D. VonHoff, Joan L. Jacob et al.
      Pages 453-458

    4. Intraperitoneal Cisplatin and Carboplatin in the Management of Ovarian Cancer

      • Maurie Markman
      Pages 459-466

    5. Radiotherapy Combined with Daily or Weekly cis-Diammine Dichloroplatinum (II) in Inoperable Non-Metastasized Non-Small Cell Lung Cancer: A Toxicity Report of the Randomized Phase III Study of the EORTC Lung Cancer Cooperative and Radiotherapy Cooperative Groups

      • C. Schaake-Koning, B. Maat, P. van Houtte, W. van den Bogaert, O. Dalesio, A. Kirkpatrick et al.
      Pages 467-470

    6. Optimizing Dose-Intensity: Combining Carboplatin with Cisplatin

      • F. M. Muggia, I. Gill
      Pages 471-480

    7. High Dose Cisplatin: Modulation of Toxicity

      • D. R. Gandara, E. A. Perez, W. Wiebe, M. W. DeGregorio, J. Hoff
      Pages 481-492

    8. Probenecid and Diethyldithiocarbamate as Modifiers of Cisplatin Toxicity

      • Charlotte Jacobs
      Pages 493-500

    9. ORG 2766 in the Prevention of Cisplatin Neuropathy

      • Ch. J. Vecht, A. Hovestadt, H. B. C. Verbiest, W. L. J. van Putten, J. P. Neyt, M. E. L. van der Burg
      Pages 501-508

    10. WR-2721 (Ethyol®): Reduction in Toxicity of Anticancer Therapy without Loss of Efficacy

      • William McCulloch, Barbara Scheffler, Philip Schein
      Pages 509-516

    11. High-Dose Cisplatin with Glutathione Protection in Gynecologic Malignancies

      • Francesco Di Re, Silvia Bohm, Rosanna Fontanelli, Saro Oriana, Francesco Raspagliesi, Gian Battista Spatti et al.
      Pages 517-528

    12. Improved Efficacy of “Two-route Chemotherapy” Using Cisplatin and its Antidote, Sodium Thiosulfate, in Combination with Angiotensin II

      • Hiroaki Kobayashi, Shun’ichiro Taniguchi, Tsuneo Baba
      Pages 529-540

  2. Back Matter

    Pages 541-545
    Download chapter PDF
Back to top

Keywords

About this book

Taken together the data presented in this review, and work by many other investigators, support the notion that DNA excision repair is important in a tumor cell's resistance to platinum compounds. Inhibition of this repair system by combination chemotherapy with the excision repair inhibitors HU and Ara-C produces synergistic cell kills and increased levels and persistance of DNA interstrand crosslinks. The studies with cis-DDP and ~-DDP in combination with UV­ induced thymine dimers suggest that there may be competition for DNA repair enzymes between the dimer and the platinum lesion. Whether the competing lesion is an intrastrand crosslink, interstrand crosslink, or platinum monoadduct (or all of these lesions) cannot be determined. The similarity between an intrastrand crosslink and a cyclobutane dimer suggests that these lesions may compete for repair. However, the increased peak levels of interstrand crosslinks, and increased persistence of these lesions at later time points suggest that this lesion may also be a substrate for the repair system. These observations may be of clinical relevance. Recently Dr. Kathy Albain of our institution has completed a Phase III I study using a 12 hour pretreatment with HU and Ara-C in patients prior to their cis-DDP therapy. She observed a significant number of responders in this trial (54). She is currently completing a second Phase IIII study substituting IV HU for the oral formulation. We anticipate initiating other clinical trials based upon these observations.

Editors and Affiliations

  • University of California, San Diego, La Jolla, USA

    Stephen B. Howell

Bibliographic Information

  • Book Title: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy

  • Editors: Stephen B. Howell

  • DOI: https://doi.org/10.1007/978-1-4899-0738-7

  • Publisher: Springer New York, NY

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Science+Business Media New York 1991

  • Hardcover ISBN: 978-0-306-44027-4Published: 29 February 1992

  • Softcover ISBN: 978-1-4899-0740-0Published: 19 June 2013

  • eBook ISBN: 978-1-4899-0738-7Published: 11 November 2013

  • Edition Number: 1

  • Number of Pages: XII, 546

  • Topics: Oncology, Immunology, Biochemistry, general

Publish with us

Policies and ethics

Back to top

Search

Navigation